News + Press

Mymetics’ HIV vaccine candidate confirms promise in preclinical study with Texas Biomed | 04.11.2016

Mymetics Corporation (OTCQB: MYMX) announced today that its innovative HIV vaccine candidate has shown to generate significant protection in groups of twelve female monkeys against repeated AIDS virus exposures during part of the preclinical study at Texas Biomedical Research Institute. | Read the full story

Discoveries Eblast - Forum Gala Update | 03.15.2016

March Discoveries e-newsletter shares news on the Texas Biomedical Forum Gala in May! | Read the full story

Collaborative Study Shows Promising Safety Results for Anti-Aging Drug | 02.09.2016

A recent collaborative study published in the November issue of the journal Aging showed minimal metabolic side effects after continuous, long-term treatment with encapsulated rapamycin in a marmoset (monkey) model. Study results have led to a new grant with the Barshop Institute to study the drug's effectiveness in the marmoset model. | Read the full story

Impact of Nonhuman Primate Research on Eye Diseases | 01.26.2016

Dr. Jeffrey Kiel, professor in the Ophthalmology Department at the University of Texas Health Science Center at San Antonio, led a recent study with co-investigator Dr. Anthony Comuzzie, Scientist in the Department of Genetics at Texas Biomed, to determine whether baboons develop retinal lesions similar to those found in human diabetic retinopathy. | Read the full story

Study Shows High Frequency of Spontaneous Mutation in Ebola Virus | 01.05.2016

In a Journal of Virology paper, Texas Biomed Scientist Dr. Anthony Griffiths, explains how he and his team found that Ebola virus has the potential to evolve rapidly but the genetic changes result in viruses that are weakened or not viable, which could be exploited as a therapeutic. | Read the full story

Texas Biomed receives $5 million grant to study possible functional cure for babies born with HIV | 12.03.2015

The National Institutes of Health have awarded scientists at Texas Biomedical Research Institute and collaborators at the Food and Drug Administration, UCLA and the University of Pennsylvania a $5 million grant over the next 4 years to study a combination antiviral drugs and investigative AIDS vaccines aimed at treating infants and children affected by HIV. | Read the full story

Texas Biomed helps test possible drug against Ebola virus | 11.20.2015

Virologists at the University of Iowa team up with scientists in the Texas Biomed Department of Virology and Immunology to test whether an already FDA-approved drug has potential as an antiviral therapy to prevent Ebola infection. | Read the full story

Pulsed xenon UV technology tested against Ebola virus and Anthrax | 11.16.2015

Xenex Disinfection Services recently tested its Full-Spectrum™ pulsed xenon ultraviolet (UV) disinfection device against live Ebola virus and Bacillus anthracis (anthrax) spores in collaboration with scientists in the biosafety level 4 (BSL-4) containment laboratory at Texas Biomedical Research Institute. | Read the full story

Discoveries - November E-Newsletter | 11.05.2015

Texas Biomed's e-newsletter is out now with the latest information on our research and scientists. | Read the full story

Texas Biomed scientist collaborates on study providing insight into genetics of Polycystic Ovary Syndrome | 08.24.2015

SAN ANTONIO (August 24, 2015) – Dr. Michael Olivier, Scientist and Chair of the Department of Genetics at Texas Biomedical Research Institute, is a contributing author on a study led and coordinated by scientists at Northwestern University Feinberg School of Medicine that was published this month in Nature Communications describing a detailed analysis of the genetic factors contributing to Polycystic Ovary Syndrome (PCOS). | Read the full story